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Abstract: The RNA interference (RNAi) pathway possesses immense potential in silencing any gene
in human cells. Small interfering RNA (siRNA) can efficiently trigger RNAi silencing of specific genes.
FDA Approval of siRNA therapeutics in recent years garnered a new hope in siRNA therapeutics.
However, their therapeutic use is limited by several challenges. siRNAs, being negatively charged,
are membrane-impermeable and highly unstable in the systemic circulation. In this review, we have
comprehensively discussed the extracellular barriers, including enzymatic degradation of siRNAs by
serum endonucleases and RNAases, rapid renal clearance, membrane impermeability, and activation
of the immune system. Besides, we have thoroughly described the intracellular barriers such as
endosomal trap and off-target effects of siRNAs. Moreover, we have reported most of the strategies
and techniques in overcoming these barriers, followed by critical comments in translating these
molecules from bench to bedside.
Keywords: siRNA delivery systems; barriers to siRNA delivery; endosomal escape; reticuloendothelial
system entrapment; renal clearance; off-target effects; immune system activation; chemical modifications;
membrane impermeability
1. Introduction
In 1998, Andrew Fire and Craig Mello published a seminal paper in which they discovered
the phenomenon of post-transcriptional gene silencing (PTGS) and termed it as RNA interference
(RNAi) [1]. Later, in 2001, two research groups reported that 21 to 22 nucleotide(nt) double-stranded
RNAs, popularly known as small interfering RNAs (siRNAs), can induce gene silencing in mammalian
cells without causing nonspecific interferon response [2,3]. siRNAs, composed of a duplex of 20 to
24 nucleotide base pairs, work by interacting with the RNAi pathway enzyme dicer for cleavage.
The single-stranded antisense strand complementary to the target mRNA is handed to the RNA- induced
silencing complex (RISC) loading complex (RLC), which destroys the target mRNA, hence silencing
the target gene or, in other words, inhibit the formation of the target protein [4]. Section 2 further
explains the mechanism of siRNA in detail. These siRNAs later kicked off a revolution in biology due
to their potential to inhibit virtually all genes by a base sequence of target mRNA alone, which gives
RNAi several advantages over small-molecule drugs as a therapeutic strategy [5]. Approval of the first
siRNA-based drug patisiran (Onpattro™) by the U.S. Food and Drug Administration (FDA) in 2018
for polyneuropathy of hereditary transthyretin-mediated amyloidosis has fostered a new interest by
the pharmaceutical as well as academic research groups in RNAi based drugs [6]. Recently in 2019,
givosiran (Givlaari™) has been approved by the US FDA for acute hepatic porphyria [7], which has
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further reinforced the confidence in siRNA based products. A timeline of these events is shown below
in Figure 1.
Pharmaceuticals 2020, 13, x FOR PEER REVIEW 2 of 25 
 
which has further reinforced the confidence in siRNA based products. A timeline of these events is 
shown below in Figure 1. 
Furthermore, dozens of siRNA-based products are already in different stages of clinical  
trials [8]. For instance, an investigational RNAi product targeting glycolate oxidase, termed 
lumasiran, is currently in phase 3 clinical trial for the treatment of primary hyperoxaluria type 1 
(PH1), in which calcium oxalate crystals are formed in the kidney and urinary tract, leading to 
recurrent kidney stones and nephrocalcinosis [9]. Lumisiran has shown promising results with 
encouraging safety and tolerability profile with no serious adverse event during the study time [10]. 
Similarly, fitusiran, another RNAi therapy, targets antithrombin (AT) in the liver, silencing AT 
gene expression, and prevents AT synthesis. Fitusiran is undergoing phase III clinical trial as a 
prophylactic treatment of hemophilia [11,12]. Also, vutrisiran is undergoing a phase-III clinical trial 
for the therapy of transthyretin amyloidosis (ATTR) with cardiomyopathy [13]. See Section 4 for more 
details on current clinical trials on siRNA therapeutics. Although several studies have shown the 
significant potential of siRNA therapeutics in-vitro, yet systemic siRNA therapy faces several 
extracellular as well as intracellular barriers for translation of siRNA therapeutics from bench to 
bedside. Several reviews have been published to address this topic comprehensively, particularly on 
the applications of siRNA therapeutics [14–16]. However, there is an urgent need for a thorough 
investigation of barriers reported in the scientific literature. Also, there have been several studies that 
describe the methods and techniques in overcoming these barriers for the translation of siRNA 
therapeutics to the clinics. Briefly, the major extracellular barriers are enzymatic degradation of 
siRNAs by serum endonucleases and RNAases, rapid renal clearance of siRNA delivery system, 
impermeability of siRNA to the biological membranes, activation of the immune system, plasma 
protein sequestration, and capillary endothelium crossing. In contrast, the intracellular obstacles to 
siRNA action are the endosomal trap, arrival at the correct intracellular site of action (cytosol), and 
off-target effects. In this review, we attempted to describe comprehensively these barriers and the 
milestones a hieved in addressing the obstacl s followed by critical commentary o  innovatio  and 
prosp cts. 
 
Figure 1. Timeline highlighting the major historical events leading up to siRNA therapeutics. 
2. Mechanism of Action of siRNA Induced RNA Interference (RNAi) 
siRNA therapies take advantage of a naturally occurring phenomenon known as RNAi. The 
mechanism of action begins with the synthesis of a generally perfectly base-paired dsRNA ranging 
from 15 to 30 bp in length [15]. The length of dsRNA plays a crucial role as siRNA smaller than 15 bp 
does not incorporate itself with the RNAi machinery. Additionally, siRNA larger than 30 bp can lead 
to cytotoxicity and nonspecific interactions via the protein kinase R (PKR) pathway [17]. Following 
the successful entrance into the cytosol via endocytosis, synthetically produced siRNAs can interact 
directly with cytosolic RNAi enzymes known as Dicer and Tar RNA Binding Protein (TRBP) [18]. 
siRNA larger than 21 bp will interact with the Dicer enzyme that cleaves and hands it off to the RNA-
induced silencing complex (RISC) loading complex (RLC) [4,19]. In comparison, siRNA shorter than 
21 bp can bypass Dicer cleavage, and through interactions mediated by TAR RNA-binding protein, 
it can successfully enter RISC. Prior to mature RISC production, the complex must successfully select 
the guide strand between the antisense and sense strand. The antisense strand is the guide strand of 
choice, and through chemical modifications, biases towards its selection are possible. The siRNA 
guide strands, or antisense strands usually have exact 100% complementarity to a single target 
1998:       
Discovery of 
post-
transcriptional 
gene silencing 
(RNAi)  by 
Andrew Fire and 
Craig Mello [1]
2001:    
Discovery of 
siRNA and its 
ability to induce 
gene silencing in 
mammalian cells 
[2,3]
2006:              
Nobel prize 
awarded to Craig 
Mello for the 
discovery of RNA 
interference 
mechanism [15]
2018/2019:         
FDA approval of 
first and seoond 
siRNA based 
drugs Patisiran 
and Givosiran 
[6,7] 
2020 (Current): 
Dozens of clinical 
trials  underway 
testing for 
efficacy of new 
siRNA therapies 
[24]
Figure 1. Timeline highlighting the major historical events leading up to siRNA therapeutics.
Furthermore, dozens of siRNA-based products are already in different stages of clinical trials [8].
For instance, an investigational RNAi product targeting glycolate oxidase, termed lumasiran, is currently
in phase 3 clinical trial for the treatment of primary hyperoxaluria type 1 (PH1), in which calcium
oxalate crystals are formed in the kidney and urinary tract, leading to recurrent kidney stones and
nephrocalcinosis [9]. Lumisiran has shown promising results with encouraging safety and tolerability
profile with no serious adverse event during the study time [10].
Similarly, fitusiran, another RNAi therapy, targets antithrombin (AT) in the liver, silencing AT
gene expression, and prevents AT synthesis. Fitusiran is undergoing phase III clinical trial as a
prophylactic treatment of hemophilia [11,12]. Also, vutrisiran is undergoing a phase-III clinical trial
for the therapy of transthyretin amyloidosis (ATTR) with cardiomyopathy [13]. See Section 4 for
more details on current clinical trials on siRNA therapeutics. Although several studies have shown
the significant potential of siRNA therapeutics in-vitro, yet systemic siRNA therapy faces several
extracellular as well as i tracellular barriers for translation of siRNA therapeutics from bench to
bedside. Several reviews have been published to address thi topic compreh nsively, particularly on
the applications f siRNA therapeutic [14–16]. However, there is an urgen need for a tho ough
investigation of barriers reported in the scientific literature. Also, there have been several studies
that describe the methods and techniques in overcoming these barriers for the translation of siRNA
therapeutics to the clinics. Briefly, the major extracellular barriers are enzymatic degradation of siRNAs
by serum endonucleases and RNAases, rapid renal clearance of siRNA delivery system, impermeability
of siRNA to the biological membranes, activation of the immune system, plasma protein sequestration,
and capillary endothelium crossing. In contrast, the intracellular obstacles to siRNA action are the
endosomal trap, arrival at the correct intracellular site of action (cytosol), and off-target effects. In this
review, we attempted to describe comprehensively these barriers and the milestones achieved in
addressing the obstacles followed by critical commentary on innovation and prospects.
2. Mechanism of Action of siRNA Induced RNA Interference (RNAi)
siRNA therapies take advantage of a naturally occurring phenomenon known as RNAi.
The mechanism of action begins with the synthesis of a generally perfectly base-paired dsRNA
ranging from 15 to 30 bp in length [15]. The length of dsRNA plays a crucial role as siRNA smaller
than 15 bp does not incorporate itself with the RNAi machinery. Additionally, siRNA larger than
30 bp can lead to cytotoxicity and nonspecific interactions via the protein kinase R (PKR) pathway [17].
Following the successful entrance into the cytosol via endocytosis, synthetically produced siRNAs
can interact directly with cytosolic RNAi enzymes known as Dicer and Tar RNA Binding Protein
(TRBP) [18]. siRNA larger than 21 bp will interact with the Dicer enzyme that cleaves and hands
it off to the RNA-induced silencing complex (RISC) loading complex (RLC) [4,19]. In comparison,
siRNA shorter than 21 bp can bypass Dicer cleavage, and through interactions mediated by TAR
RNA-binding protein, it can successfully enter RISC. Prior to mature RISC production, the complex
must successfully select the guide strand between the antisense and sense strand. The antisense strand
is the guide strand of choice, and through chemical modifications, biases towards its selection are
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possible. The siRNA guide strands, or antisense strands usually have exact 100% complementarity to a
single target mRNA which allows for the potent and successful silencing of the gene. Following the
successful loading of the guiding stand, TRBP and Dicer have the ability to dissociate from RISC.
Ago2, which is an enzyme that joins and associates itself with the RLC, plays an important role for gene
silencing as it has intrinsic silencer activity to efficiently cleave the mRNA targets [20]. Gene expression
is regulated through the inhibition of mRNA translation in the form of inducing mRNA sequestration
in cytoplasmic processing bodies (P bodies) and/or GW bodies, which ultimately promotes mRNA
degradation and directing transcriptional gene silencing of the target gene [21–23]. Figure 2 illustrates
the mechanism of siRNA action.
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3. Advantages of siRNA over Other RNAi Therapeutics
There are several types of RNAi therapeutics: micro RNA (miRNA), short hairpin (shRNA),
and siRNA. miRNA is a single-stranded RNA that has the stem-loop structure and binds imperfectly to
mRNA. Due to this characteristic, miRNA can degrade many sets of similar mRNAs, causing toxicity [24].
shRNA has a tight hairpin structure, making it more complicated than other RNAi therapeutics.
It requires the promoter to be expressed and located in the nucleus to act appropriately [25].
Lastly, siRNA is the short stretch double-stranded RNA that can degrade the complementary mRNA.
siRNA has high transfection efficacy and fewer obstacles, making the best fit for RNAi therapeutics [26].
Table 1 illustrates the different types of RNAi therapeutics.
Table 1. Types of RNAi therapeutics.
Type of RNAi Silent Feature of RNAi Therapeutics References
miRNA
Stem-loop structure
Binds imperfectly to mRNA and degrades many sets of similar
target mRNA
[24]
shRNA
RNA with a tight hairpin turn
Requires promoter to be expressed and must be located in the
nucleus to act
[25]
siRNA Short stretch dsRNA capable of degrading complementary mRNAHigher transfection efficiency and fewer obstacles. [26]
4. siRNA-Based Therapeutics in Clinical Trials
Many siRNA-based therapeutics are making their way onto the clinical trial stage for a multitude of
diseases. The following clinical trials are specific to therapeutics to treat cancer. Although many of these
therapeutics did not make their way to Phase II trials, some have been more recently modified, making its
way back to the clinical stage. An investigational siRNA therapeutic is CALAA-01 from Calando
Pharmaceuticals [18]. This therapeutic is a four-component polymer-based nanoparticle siRNA delivery
system around 75 nm in diameter [27,28]. The complex consists of a linear, cationic cyclodextrin-based
polymer known as adamantane polyethylene glycol or PEG, which is incorporated to provide steric
stabilization, along with a human transferrin protein-targeting agent and a siRNA that targets the
reduction in the M2 subunit of ribonucleotide reductase (RRM2) expression [18]. Existing data reveals
that RRM2 plays a large role during nucleic acid metabolism and is upregulated in many tumor
types [18,27–29]. It is proposed that the suppression of RRM2 will lead to cell cycle arrest and
cell death [30].
Another therapeutic investigation was from Alnylam Pharmaceuticals named ALN-VSP.
This siRNA-based therapeutic is a nearly neutral nanoparticle formulation about 80-100 nm in
diameter, with two different chemically modified siRNAs targeting different proteins, in a 1:1 molar
ratio [31,32]. The siRNAs individually target vascular endothelial growth factor A (VEGFA) and kinesin
spindle protein (KSP). Both KSP and VEGFA are highly expressed in a variety of tumor types [31],
where VEGF is proposed to modulate tumor angiogenesis or the growth of blood vessels to supply
nutrients to tumors, and KSP is essential for mitotic spindle formation in proliferative cells [31].
Targeting of VEGF is proposed to decrease blood supply to the tumor, and KSP is targeted to stop
mitotic spindle formation [31].
Atu027, developed by Silence Therapeutics, is a cationic lipoplex-based siRNA delivery system
made up of a blunt-ended, chemically modified 23-mer RNA oligonucleotide along with three cationic
lipids. The siRNA is created to target protein kinase N3 (PKN3). It is proposed that PKN3 suppression
stabilizes vessel integrity and attenuate inflammatory responses in the vasculature of tumors and
secondary organ sites via modulation of actin and adherin junction dynamics [18,33,34]. Furthermore,
this will ultimately lead to inhibition of mobilization and engraftment of metastatic tumor cells due to
the reduction of both tumor and host vascular permeability [18].
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Other therapeutics termed TKM-PLK1 from Tekmira carried a siRNA targeting polo-like kinase 1
(PLK1). It is a lipid nanoparticle about 80 nm in diameter targeting PLK1. It is thought to be a key
protein during multiple steps in cell division, DNA stability, and DNA repair. It has also been found to
be upregulated in many human tumors. It is proposed that the silencing of PKL1 may induce apoptosis
and tumor cell death [35].
Another reported therapeutic is PN2258 from ProNAi Therapeutics, which is a liposomal
formulation around 130 nm in diameter. It comprises a 24-base chemically unmodified DNA
oligonucleotide and four lipid molecules, making the therapeutic unique as it does not contain
siRNA [36]. Since it does not contain siRNA, the RNAi mechanism at the RISC complex is not induced.
It was included with the other clinical trials because it is systematically administered and is a nucleic
acid formulation for anticancer treatment. The nucleic acid portion, also known as PNT100, follows a
mechanism where it binds to the 5′-untranscribed regulatory regions of the BCL2 protein gene and
blocks transcription via DNA interference rather than RNA interference.
5. Barriers to siRNA Delivery
As described earlier, small double-stranded RNA (ds RNA) molecules can efficiently trigger
the post-transcriptional gene silencing; still, their delivery has been the major challenge to applying
siRNA-based therapeutics in humans [37,38]. Barriers depend on the target organ and the desired
route of administration of siRNA. The affluence of siRNA delivery depends on the accessibility of
target tissue or organ inside the body. Broadly two administration routes, localized administration,
and systemic administration, are used. Localized siRNA delivery has fewer barriers than systemic
delivery. In localized delivery of siRNA, therapy is applied directly to the target organ or tissues,
offers high bioavailability at the target site, and avoids the barriers that are shown by the systemic
administration [39]. Several organs are compliant to local or topical siRNA delivery, including eyes,
mucous membranes, localized tumors, and skin [40,41]. Lungs infections can be treated with local
siRNA delivery; direct installation of siRNA through intranasal or intra-tracheal routes permits direct
contact with epithelial cells of the lungs [42]. Readers are encouraged to read excellent reviews about
physical and immunologic barriers of local delivery of siRNA [43,44].
In contrast, the siRNA systemic delivery has various challenges that limit the siRNA bioavailability
at the target site [45]. Upon intravenous injection, unmodified naked siRNA is degraded by endogenous
enzymes. Also, due to their small size (MW 13 kDa), siRNA is eliminated through kidneys. The siRNA is
a negatively charged molecule, and it is almost impossible for siRNA to cross the biological membrane.
The half-life of most naked or unmodified siRNA is between 5–10 min [46]. Table 2 illustrates the
barriers faced by siRNA to reach its site of action. These barriers limit the application of siRNA-based
therapeutics in humans and warrant specific chemical modifications of either siRNA or the delivery
system for their widespread use in clinical conditions.
Table 2. Barriers faced by siRNA to reaching site of Action.
Extracellular Barriers Intracellular Barriers
Endogenous Nucleases Endosomal trap
Elimination through kidneys due to small size Arrival at the correct intracellular site of action (cytosol),
Impermeability to biological membranes Off-target effects.
Entrapment by Reticuloendothelial System
Plasma protein sequestration
Capillary Endothelium Crossing
6. Intravascular Degradation and Renal Clearance
The first biological barrier after injection is intravascular degradation of siRNA by nucleases
enzyme in plasma. The naked or unmodified siRNA is unstable in the systemic circulation and more
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susceptible to A-type nucleases, which are ubiquitous in intracellular and extracellular space [47].
Besides, fast renal clearance results in the very short half-life of siRNA, ranging from 5–10 min [48–50].
Nucleases in plasma or tissues degrade the unmodified siRNA in few minutes to 1 h, potentially limiting
the use of siRNA-based therapeutics [51,52]. The reason for these challenges is attributed to their small
size, approximately 7 nm in length and smaller molecular weight, i.e., approximately 13 kDa [53].
To this end, siRNA modification is necessary to resist nuclease mediated degradation, reducing siRNA
susceptibility towards nucleases and improving their in-vivo properties. However, siRNA modification
alone may not be enough to achieve the therapeutic activity. In this way, physical encapsulation of
siRNA and chemical modification promotes proper therapeutic activity [54,55].
Researchers have turned on modifying the sugars, backbone, or bases of oligoribonucleotides for
stabilization to overcome intravascular degradation [56]. The modification of base with internal uridine
to rF (2,4-difluorotoluyl ribonucleoside) substitutions shows better resistance towards intravascular
degradation by nucleases in the serum [57]. Modification of both the sense and antisense strand enhances
the nuclease resistance in the serum [58]. In the case of sugar modifications, 4′-thioribonucleosides
modification shows higher resistance towards serum nucleases [59]. If ribose 2′-OH group modified
with a CH3 group or fluoride atom within both the sense as well as antisense strand, enhanced their
resistance towards endonucleases and also improved therapeutic potency of siRNA [60]. A study
demonstrated that the siRNA modified with the 2′fluoro group significantly enhanced resistance
towards nucleases in plasma but unable to generate prolonged silencing in mice and cell cultures [61].
Figure 3 illustrates these modifications. It has been suggested that modification of siRNA with small
molecules such as 2,4-dinitrophenol (DNP) not only increases their ability to resist nucleases, but it also
enhances their membrane impermeability [62]. Some reputed modifications of siRNA are presented in
Table 3.
Table 3. Characteristics of siRNA modifications.
Modification Type of Modification Outcome Reference
Base
Internal uridine to rF
(2,4-difluorotoluyl ribonucleoside)
substitutions
Enhanced resistance towards
serum nucleases [57]
Sugar
2′-Deoxy-2′-fluoro-β-D-arabino,
2′-O-MOE modification,
2′-O-Me modification
Increase the half-life in the serum [63]
Locked nucleic acids Longer half-life reducesimmune activation [64]
4′-Thio modified the ring oxygen Enhanced resistancetowards nucleases [65]
Backbone
Phosphorothioate (PS)
modifications
Morpholino oligomers
The longer half-life of duplex
More potent [66]
Extensive chemical modification of siRNA showed high in-vivo efficacy. For instance,
siRNA modification of the sense strand comprised of 2’F-pyrimidines, 2’-deoxypurines with 5’- and
3’-terminal inverted a basic end caps. While, the antisense strand comprised of 2’-fluoro-substituted
pyrimidines, 2’-methoxy purines with a single phosphorothioate (PS) linkage at the 3’-terminus,
gives prolonged half-life in the serum, reaching 2 to 3 days as compared to naked unmodified siRNA
with half-life minutes to less than 1 h [67]. However, the extended chemical modification screening
process elaborated that improved serum stability can be achieved by thermodynamic stabilization
selectively of some positions within the duplex compared to the thorough substitutions of siRNA with
several analogs [68,69].
One of the main mechanisms of removing the siRNA therapeutics from the bloodstream is through
urine by glomerular filtration in the kidneys. The pore size of the glomerular filtration barrier is about
8 nm [70], so if the nanoparticles are designed to have a particle size of about 20 nm, this barrier
challenge can be addressed efficiently [70]. There are variable reports about the half-life of unmodified
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siRNA in serum, several studies suggest that chemically modified siRNA lasts longer in nuclease
rich environment than the unmodified siRNA [71]. Furthermore, increasing its molecular weight by
attachment of ligands, incorporating larger particles, or binding to plasma proteins efficiently saves
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resistance to nucleases with greater serum stability and prolonged circulation time [72]. In another
study, it observed that cholesterol-siRNA conjugate resulted in greater stability and silenced the
endogenous gene expression of apo B protein, which regulates cholesterol metabolism [74]. On the
other hand, naked siRNA without cholesterol conjugation did not show any silencing activity inside
the cell [74].
Conjugation with polymer, especially PEG, is a common concept to increase the half-life of siRNA in
blood and enhance the pharmacokinetic profiles [46,75]. A study demonstrated that conjugating siRNA
with 20k PEG resulted in a slower rate of renal clearance (50% remained 1 h after injection) as compared
to unmodified siRNA (<10% remained 15 min after injection) [76]. Similarly, the conjugation of PEG at
2-nucleotide 3’-overhang significantly increased the downregulation of PSMA expressing tumors [77].
Besides, siRNA-cationic polymer showed 100-fold more retention time in blood than naked
siRNA [78]. The cationic RNAi nanoparticles (NPs) were also shown to be excreted through kidneys.
The primary reason may be their interaction with anionic proteins on the capillary wall of the
glomerulus; the resulting neutralization may have resulted in the ready release of siRNA on the
capillary bed of glomerulus with subsequent excretion. To overcome this barrier, cationic RNAi NPs
may also be PEGylated to reduce renal clearance and increase the circulation time of siRNA [55].
Another study showed that cationic comb-type copolymers (CCC), having a considerably higher
density of hydrophilic graft chains, increased the stability of siRNA against nuclease and plasma
components. The siRNA complexed with CCC acquired considerably longer blood circulation than
naked siRNA or complexed with PEI (jetPEI™) [78].
7. Activation of the Innate Immune System
The function of innate immunity is to identify the pathogens, eradicate them, and contribute
to adaptive immunity. Host cells depend on the pattern recognition receptors that detect infectious
and non-self-agents, including lipopolysaccharide, viral RNAs, bacterial DNA, viral glycoproteins,
and peptidoglycan [79].
Previously, it was thought that siRNA shorter than 30 nucleotides were small enough
to evade the immune system and avoid nonspecific stimulation of interferon response.
However, subsequent experiments with short synthetic siRNAs showed that siRNA could activate
the immune response and trigger the production of cytokines in-vivo and in-vitro [80]. This innate
immune response can be triggered by the siRNA or by the vehicles, including cationic lipids used to
deliver siRNA in-vivo [81].
Mammalian cells possess immune cells that express pattern recognition receptors named as
Toll-like receptors (TLR). These receptors recognize foreign pathogen-associated structural patterns.
This immune response can be activated either by TLR dependent or TLR independent pathways [79].
7.1. TLR Dependent Pathway
In TLR dependent pathway, thirteen TLR receptors have been recognized in humans as well
as the mouse. Among these receptors, three TLR receptors, including TLR1, TLR2, and TLR3,
have been identified to be triggered in response to siRNA [82]. TLR3 recognizes the duplex siRNA
in a sequence-independent manner. Meanwhile, TLR7/8 recognizes the siRNA in a sequence-
dependent manner. The example of sequence-dependent immune response by TLR7/8, the uridine,
and guanosine-rich sequences with either UG dinucleotide or 5′-UGU-3′ potently trigger the innate
immune response [82]. Avoidance of such sequences decreases the immune response [80]. Also, AU rich
patterns have shown greater influence on TLR8 response [83]. Signaling by these intracellular TLR
receptors requires acidification of endosomes along with maturation. Therefore, this endosomal
acidification can be inhibited by the use of chloroquine or by buffering agents [84].
TLR3 possesses a specific gene structure among the TLR receptors and linked to its subfamily
dissimilar from TLR7/8. At the cellular level, TLR3 expression in human leukocytes is vastly restricted
to mature dendritic cells (mDCs). While in mice, TLR3 is found in a vast variety of immune cells.
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Recently, TLR3 expression on the cell surface has been noted in primary human endothelial cells such
as lung, aorta, dermis, choroidal, and umbilical vein. TLR3 can also be present in several other cells,
including epithelial, endothelial, and fibroblast lines [85]. Alexopoulou et al. demonstrated that dsRNA
act as a TLR3 agonist by examining the response of splenocytes, macrophages, or bone marrow-derived
DCs in TLR3 knockout mice to polyinosinic–polycytidylic acid (polyIC), a long synthetic dsRNA
homolog [86]. TLR3 receptors on the surface of endothelial cells can also be activated by exogenous
siRNA of 21 nucleotide base pairs in-vivo, resulting in the release of cytokines such as IL-12 and IFNγ.
Unlike the various nucleic acid-sensing TLR receptors, that signal through the MyD88, TLR3 receptor
signals through the TRIF adaptor protein [87]. TRIF signal is generated for the production of IFNβ
along with IFNα4 by TANK-binding kinase-1 (TBK1), leading to the activation of transcription factor
IRF3, which results in a positive feedback phenomenon to cause TLR3 signaling. This mechanism leads
to the production of IFNβ and IFNα4 signals back to the cell, causing the up-regulation of IRF7 and
other IFN-inducible genes. TLR3 activation via TRIF also activates RIP1 and TRAF6, leading to the
activation of ATF, NF-κB, and c-Jun transcription factors along with the induction of inflammatory
cytokines such as IL-6 and TNFα [88].
As discussed earlier, TLR7 and TLR8 recognize the siRNA in a sequence-dependent manner. It has
been observed that plasmacytoid dendritic cells (pDCs), B cells, and monocytes express TLR7. At the
same time, TLR8 is expressed by myeloid DC (mDC) and macrophages in humans [89]. TLR7 has been
shown to detect single-stranded RNA (ssRNA), polyuridine, as well as synthetic ssRNA rich in uridine
along with guanosine [90]. Similarly, TLR8 recognizes AU-rich and GU-rich ssRNA, and RNA viruses
also trigger it. siRNA duplexes with GU-rich sequences or identified 5′-UGU-3′motifs within particular
siRNAs confer this highly immunostimulatory activity [81]. According to studies, it has been stated
that TLR7/8 recognizes the siRNA in a sequence-specific manner [91]. Several immune-stimulatory
signaling mechanisms are stated in Table 4.
Table 4. TLR-dependent signaling in response to siRNA sequences.
Sequence Signaling Mechanism Type of Cytokines References
5′-GUCCUUCAA-3′ motif TLR8 Interferon-α [92,93]
GU-rich sequence TLR7 IFN-α [94]
AU-rich sequence TLR7 and TLR8 IFN-α, tumor necrosis factor (TNF)-α [95]
5′-UGUGU-3′ TLR8 IFN-α [92]
Repetition of uracil TLR7 interleukin-6 and TNF-α [96]
Avoiding uridine and guanosine motifs may reduce a sequence-specific immune response.
The replacement of siRNA motifs with adenosines may also abrogate the immune activation [97].
Interestingly, replacement of 2′-hydroxyl uridines with 2′-fluoro, 2′-O-methyl, or 2′-deoxy uridines
blocks the immune activation. Thus, RNA immune recognition by TLRs can be prevented using
2′-ribose modifications of uridines [82]. The addition of 2′-O-Me uridine and guanosine into the sense
strands of siRNA forms non-inflammatory siRNA without reducing their activity, and also protect
the 5’ end of the guide strand that is vulnerable towards exonucleases [98]. As discussed earlier,
chloroquine and bafilomycin A1 inhibit endosomal acidification and block the TLR3, TLR7, and TLR8
of siRNA without interfering with their RNAi activity [99].
7.2. TLR Independent Pathway
In TLR independent pathway, cytoplasmic RNA sensors such as retinoic acid-inducible
gene 1 (RIG-1, also known as DDX58), melanoma differentiation-associated gene 5 (MDA-5),
and dsRNA-binding protein kinase (PKR) are included [88]. It has been reported that RIG-1 binds
to either ssRNA or dsRNA with uncapped 5’triphosphates, leading to the production of IFN.
Therefore RIG-1 expression is readily upregulated in the para or autocrine manner, following the
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interferon response [100]. RIG-I and MDA5 activate the common downstream adaptor molecule
MAVS. Activated MAVS then recruits multiple signaling molecules, including TRAFs, TBK1,
and IRF3/7, leading to the transcriptional upregulation of type I interferons and other proinflammatory
cytokines [101]. Finally, dsRNA-dependent PKR phosphorylates the serine along with threonine
residues of the target protein. In humans, most of the cells express a low level of PKR and thus
remain inactive. However, PKR binding to dsRNA leads to the formation of the dimer that ultimately
undergoes autophosphorylation and subsequent activation of the pathway [102]. It has been suggested
that the detection of dsRNA by PKR is a sequence-independent manner and interferon presence
upregulates its expression [103].
8. Protein Binding
To achieve cell permeation of siRNA for effective concentration within the cell, a positively
charged carrier is an essential requirement. Blood complement proteins and cell membrane proteins
are usually negatively charged in the systemic circulation. The surface of the siRNA loaded carrier
is positively charged, and it can be readily opsonized by opsonin proteins or may cause un-specific
interaction with the cell membrane proteins [104]. Opsonins are essentially blood complement proteins
or immunoglobulins. These blood complement proteins bind with the positively charged siRNA
carriers through electrostatic interaction. The opsonization mechanism can occur anywhere in the blood
circulation, completing from seconds to days. The opsonized carriers then undergo reticuloendothelial
system (RES) filtration, and their cell surface binding leads to inflammation. The opsonization
process makes siRNA carriers more susceptible to RES filtration and results in fast renal clearance
(Figure 4) [55]. Opsonized carriers loaded RNA drugs accumulate in the liver and spleen and may
cause toxic effects [105]. Thus, ultimately opsonization process reduces the therapeutic concentration
needed for their efficient RNAi activity [55].
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Surface modifications are the primary strategies to reduce the interaction between opsonin proteins
adsorption and RNAi carriers. Coating of positively charge carriers with hydrophilic polymers such
as PEG or specific synthetic polymers significantly decreases the opsonization along with unspecific
binding [105,106]. For example, palmitate-avidin containing PLGA carrier adsorbed PEG-biotin on
their surface, and the 10 kDa PEG-coated particle reduced protein adsorption by 75% [107].
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9. RES Entrapment
As listed earlier, a major problem is the uptake of nucleic acid drugs by the RES. RES/mononuclear
phagocytic system containing organs, including the liver, spleen, lung, and bone marrow, are saturated
with the fenestrated capillaries along with phagocytic cells, macrophages, and monocytes [108]. It is
thought that nanoparticles greater than 100 nm are trapped by RES in the liver, bone marrow, spleen,
and lung, leading to degradation by activated monocytes and macrophages [108]. siRNA loaded
nanoparticles undergoing the opsonization process are readily removed by the macrophages in RES [55].
Once the siRNA therapeutics reach the bloodstream, they have to be protected from the phagocytic
cells of the mononuclear phagocyte system (MPS) [70]. The uptake of siRNA-nanoparticles from blood
circulation to RES organs is quite a fast process. Still, these carriers are processed and eliminated
slowly, resulting in prolonged retention of these particles in the filtering organs [55]. Somehow, the RES
filtration process of specially siRNA-based therapeutics becomes helpful sometimes when the desired
organ is a RES-rich organ [39].
Numerous factors, such as surface features, charge, and size of the carrier, may interfere with RES
uptake and bio-distribution. It is thought that a surface with a negative charge is more susceptible
to clearance from blood as compared to positive or neutral charged carriers. Surface modification
is the primary strategy to bypass this barrier [39]. For example, siRNA carriers can be grafted with
hydrophilic polymers such as PEG and other surfactant copolymers such as polyethylene oxide and
poloxamers that give them stealth properties and cause them to remain in the blood for a prolonged
time [109,110]. These modifications resist the protein adsorption, thereby protect the siRNA against
opsonization and ensure cargo stability. These stealth properties are efficient for particles ranging from
70–200 nm. It is interesting to note that more pegylation may also neutralize the positive charge of
the surface needed for the siRNA uptake into the cells [39]. Hence customized pegylation is required
that causes the carrier to evade RES, but meantime does not compromise the cellular uptake of
siRNA. For instance, if pegylation of siRNA-lipoplexes is increased from 1–2 to 5 mol% of PEG2000,
it completely eradicates the siRNA-mediated gene silencing against PTEN protein in-vitro [111]. It is
noteworthy that the pegylation strategy needs further exploration to identify the size and molecular
weight of the PEG for designing an optimum siRNA delivery system.
10. Membrane Impermeability
As discussed earlier, naked siRNA cannot cross the plasma membrane because of its negative
charge. Despite its small size, the negative charge and high hydrophilicity prevent siRNA from
passing through the biological membrane. Hence, efficient delivery of siRNA needs modification
to overcome this barrier [112]. In this context, carriers that enable efficient siRNA delivery are
required. Complexation of siRNA with cationic polymers or lipids can mask the net negative charge of
siRNA. Furthermore, these nanoparticles with positive charge interact with the negatively charged
biological membrane, thus causing internalization [113]. Alternatively, efficient delivery of siRNA can
be achieved by conjugating the siRNA with ligands, immunoglobulins, or aptamers that recognize
specific antigens on target cells. When these conjugates bind to the cell, the siRNA uptake is done by
receptor-mediated endocytosis resulting in endosomes formation with subsequent siRNA delivery
into the cytoplasm [112]. Figure 5 illustrates this concept.
Due to the hydrophilicity and negative charge of the siRNA, various carriers are used, including
cationic polymers and peptides. Peptides, in particular, have received specific attention because they
show great promise as siRNA carriers, based on the diversity of their physiochemical properties
and functions. Based on the function, several classes of peptides, including cell-penetrating peptides
(CPPs), endosome-disrupting peptides, and non-covalent multifunctional peptide complexes, can be
used [114]. CPPs, also referred to as protein transduction domains (PTD), can penetrate the plasma
membrane of a cell and facilitate the delivery of various cargoes. Moreover, the cytotoxicity of CPPs is
relatively low [115]. For instance, Tanaka et al. reported stearic acid conjugated a CPP demonstrated
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that injecting STR-CH2R4H2C peptide with siVEGF suppressed the tumor growth efficiently compared
with naked siRNA or controlled group [116].
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11. Endosomal Escape
Following the internalization of the siRNA, a major barrier remains to be its inability to escape
endosomes. Thus, a carrier or modification that allows for the disruption of the endosomal membrane
is essential for efficient endosomal escape and gene silencing by siRNA. Many recent delivery vehicles
have taken advantage of the change from extracellular to the endosomal environment. Among the
many differences, the change in pH is often utilized for efficient endosomal disruption and further
release of siRNA once inside the target cell [117]. Protonable cationic polymers have been shown to
increase elivery efficiency due to their high buffering capacity [45].
Sev ral endosomolyti agents su h as polymers, proteins, peptides, and small molecules like
chloroquine can als be employed i siRNA ca ri r formulations to avoid the e dosomal trap 18].
These carrier increases the counter-ion concentrati ns, leading to osm ic swelling, endosomal
membrane rupture, and the ubsequent escape int the cytosol [119]. A prime example f a positively
charged polymer is polyethyleneimine (PEI), which can act as a “proton sponge” and facilitate the
endosomal release of siRNA. The proton sponge effect facilitates the chloride ion influx and destroys the
endosomes with subsequent release of contents into the cytoplasm [119]. The “proton sponge” effect or
proton absorbance by buffering polymers such as PEI is known to increase the ATPase-mediated influx of
protons and counter ions credited to their ability to prevent acidification [120]. As a result, the increased
counter ion concentration inside the endosome leads to osmotic swelling, and ultimately endosomal
membrane rupture, releasing the carrier and siRNA into the cytosol [121]. Although the PEI has this
capability, one of the major drawbacks is its cytotoxicity, known to increase along with its physical
size [121]. Another reported agent for causing effective endosomal escape is poly(lactic-co-glycolic acid)
(PLGA) [122]. PLGA is a copolymer, biodegradable, biocompatible, and helps in RNAi activity of the
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siRNA. PLGA provides a sustained release to the siRNA with increased cellular uptake [122]. Especially,
the layer-by-layer complex (nanoparticles) with PEI and PLGA increases the endosomal escape
efficiency [122]. Another strategy for endosomal escape is protonation; two amino acids arginine
and lysine get protonated in low pH that lead to destabilizing of cellular membranes. Lysine- and
arginine-based polymers covalently linked to siRNA formulation have been used extensively to induce
the release of siRNA from endosomes into the cytoplasm [123].
Additionally, recent reports have cited the development of a PEG-based cleavable polymeric
system, composed of nonlamellar highly fusogenic lipid nanoparticles that are further stabilized
by surface-exposed PEG-conjugated vinyl ether lipids [124]. Its mechanism of action involves the
hydrolysis of the vinyl ether bond at low pH inside of the endosomal environment, which results in
the destabilization of the liposome and removal of PEG (Figure 6) [45]. This destabilization allows for
the fusion between the liposome and endosomal membrane, ultimately releasing the siRNA in the
cytosol efficiently, escaping the endosome [124].
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12. Off-Target Effects
In terms of siRNA formulation to accumulate in tumors, specifically, it is only around 20 to
40% higher than that of normal tissue [128]. The enhanced permeation and retention (EPR) effect,
which stems from leaky blood vessels in tumors, allows for the preferential uptake of the formulation in
tumors compared to normal tissue but is not significant enough and may ultimately cause more harm
than good in the long run [128]. Thus, to overcome these off-target effects, the use of surface-ligand
modifications for siRNA formulations have recently been utilized for more targeted delivery of cargo.
Many tumors and other diseases overproduce cell-surface receptors that can be preferentially targeted
through the modification of a carrier with surface ligand modifications. To overcome the off-target
effects, the receptor-targeted-delivery, conjugation with antibody, and chemical modification have
been used.
First, receptor-targeted-delivery targets the specific receptors that are expressed in the specific
type of tissue. This approach can directly deliver to the specific tissue and overcome the off-target
effects. For example, researchers conjugated GalNAc ligand onto the siRNA to treat liver disease [129].
The drug based on GalNAc conjugation, givosiran, was approved by the FDA, as mentioned earlier
in the introduction. GalNAc is one of the examples where modification was done at 3’ terminus
of the sense strand. GalNAc conjugation bind to a receptor called ASGPR, also known as the
asialogycoprotein receptor, which is responsible for uptake and clearance of circulation glycoprotein
through a process of receptor binding to terminal galactose moieties followed by endocytosis [129].
This conjugate increased about 5-fold RNAi activity in vivo. During the experiment of targeting TTR
mRNA, also known as transthyretin mRNA, the significant amounts of TTR mRNA were reduced in
the liver cells, hepatocytes [130]. Besides, the PS (phosphorothioate) linkage modification of GalNAc
conjugate improved the protection of 5’-exonuclease and required the lower dose of siRNA. Further
research showed that not only triantennary but also the monovalent GalNAc conjugation improved
the binding affinity and gene silencing efficiency [130]. The chemical modification may also prevent
off-target effects [131]. Table 5 illustrates these chemical modifications. Particularly incorporating
2’-O-methyl modification of position 2 into one strand of the siRNA reduced the off-target effects and
off-target mRNA [131]. As discussed earlier in Section 4, the use of transferrin protein to target the
transferrin receptor, which is upregulated in various human tumor cells, is common [132]. Specifically,
CALAA-01 made it onto the clinical stage and was tested in a cancer clinical trial [18]. Although the
trials were discontinued after Stage I, fluorescence-based microscopy utilizing a CALAA-01 specific
stain revealed the accumulation of the therapeutic within tumors but not in adjacent healthy tissue [18].
Table 5. GalNAc conjugation to overcome off-target effects.
GalNAc Conjugation Modifications Results References
Triantennary
-Added PS linkages for the
protection against the
5’-exonuclease.
-Reduced the off-target effects.
-silenced mTTR in the liver cell
(hepatocytes)
[131]
Monovalent
-2’ and 4’of the RNA’s ribose
sugar backbone for GalNAc
linker conjugation.
-Similar or better binding
affinity and gene silencing
efficiency compared to
Triantennary GalNAc.
[130]
Additionally, in various tumors, it is possible to target the blood vessels supplying nutrients
to the tumor through surface modification with peptide ligands. Among the many peptides, cyclic
RGD (cRGD) is among the most commonly used modifications. cRGD can be isolated from in vivo
tumor phage selection display and preferentially binds to avβ3 and avβ5 integrins. It is overexpressed
on angiogenic endothelial cells of various tumor types and even on the tumors themselves [128].
cRGD is known to bind to integrin receptors 100-fold more tightly than linear RGD, making it the
peptide of choice for surface modification [133]. A functionalized chitosan nanoparticle targeting
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PLXDC1 (a receptor highly expressed in tumor vasculature) inhibited ovarian tumor growth by
about 90%. The modified cRGD nanoparticle showed to be 60% more effective than non-modified
nanoparticles [134]. It is important to note that these peptide modifications to target blood vessel
endothelial cells are yet to make it onto the clinical stage and is currently mainly being tested in
murine models.
Finally, the antibody conjugation with siRNA may also minimize the off-target effects.
During the experiment, antibody complex F105-p-siRNA was specifically delivered into HIV-infected
Jurkat cells without triggering any interferon responses and delivering to adjacent cells [135].
Besides, another experiment of inhibiting the growth of B16 tumors, antibody-siRNA complex,
was able to successfully prevent the growth, which explains that the antibody-siRNA complex has
great therapeutic potentials [135]. Figure 8 explains general mechanism of ligand-receptor mediated
targeting and siRNA delivery.
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13.1. Aptamer-siRNA Conjugation
The aptamer is a single-stranded oligonucleotide with a three-dimensional structure that can be
used to target cells. Their high affinity as well as specificity towards specific molecules, make it similar
to monoclonal antibodies. However, aptamer shows several advantages over antibodies as they possess
little-to-no toxicity and immunogenicity [136]. Both aptamer and the siRNA are nucleic acids, so both
can be combined with simple covalent linkage or complementation (annealing). This combination of
two has been mentioned as aptamer-siRNA conjugates [137]. Researchers can identify aptamers from
libraries (>1014 shapes per library) by using a technique termed as SELEX (Systematic Evolution of
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Ligands by Exponential Enrichment) proposed by Gold and Szostak in 1990 [138]. Two different research
groups first defined aptamer mediated siRNAs delivery. In both types of research, prostate-specific
membrane antigen (PSMA) targeting RNA aptamers were used. PSMA is the first cancer cell-specific
marker protein used for siRNA delivery with the help of aptamers. For critical metastatic cancer,
an aptamer identifying alpha V and beta 3 (αVβ3) integrin were selected and linked to a siRNA against
eukaryotic elongation factor 2, inhibiting proliferation and inducing apoptosis in target cells [139].
The last decade has seen several aptamers that bind to cell surface receptors, and upon ligand binding,
it causes active internalization of cargoes, especially siRNA [140]. Table 6 illustrates the application of
aptamers for delivery applications of nucleic acids.
Table 6. Aptamers based on cell surface protein along with their delivery applications.
Receptor Selection method RNA/DNA Delivery Applications References
Transferrin receptor (TfR) The extracellularpurview of mouse TfR RNA/DNA
Protein involved
targeting lysosome [141]
Nucleolin N/A DNA Imaging variety of tumors [142]
Tenascin C (TN-C) Purified TN-C RNA Imaging variety of tumors [139]
Prostate-specific membrane
antigen (PSMA)
The extracellular
purview of PSMA RNA
Cellular imaging, siRNA
delivery along with
anticancer drug delivery
[143,144]
Epidermal growth factor
receptor (EGFR)
The extracellular
purview of EGFR RNA Delivery of nanoparticles [145]
13.2. Exosomes for siRNA Delivery
Another evolving innovative siRNA delivery vehicle is exosomes. Exosomes are naturally
occurring RNA carriers that regulate the gene expression of recipient cells. Exosomes have been
exploited for their use in delivering the siRNA within the cells [146]. They can bypass the several
barriers encountered by other delivery vehicles for siRNA. Exosomes possess several advantages over
other carriers, including greater delivery efficiency, membrane crossing capacity, biocompatibility,
and non-immunogenicity [147,148]. Exosomes also show less toxicity and better safety while delivering
the siRNA into the cells [149]. Besides, exosomes comprise of a specific protein and lipid composition
that makes them suitable in delivering various cargoes directly to the cytosol through fusing with
biological membranes [147]. Exosomes are nano-sized (40–100 nm) extracellular vesicles, and their
design is based on endosome [150]. Once exosomes reach the desired target cells, their uptake can
be mediated either endocytosis or fusion with biological membrane followed by internalization of
siRNA in the cytosol [151]. Exosomes possess a slightly negative charge that is the reason for their
stability in the blood. Besides, exosomes are more compatible with the immune system and do not
trigger the immune response and have been reported to avoid off-target effecrs [152–154]. One of the
most promising ability of exosome is to cross several biological barriers especially blood brain barrier
(BBB), that warrant their potential use in several neurological disorders [155].
14. Innovations and Prospects
Besides its effectiveness, siRNA-based therapeutics face several challenges that limit their potential
from bench to bedside. Nevertheless, numerous successful in-vitro studies and several investigations
aimed at addressing the challenges for clinical application of siRNA therapeutics engenders great
hope in this field. RNAi gains popularity in the scientific community quickly due to its potential
to cause targeted knockdown of gene expression. Also, a great advancement in siRNA experiment
protocols, easy availability of siRNA reagent kits, fast and efficient means to tailor siRNAs specific
to desired sequences, latest bioinformatics software, and availability of the whole of the genome
has made siRNA a lucrative tool for the cancer therapy as well as other intractable ailments [156].
A recent review delineates in detail the use of bioinformatics tools, software packages, and protocols
in helping to design precise siRNA sequences for silencing desired genes and avoiding off-target
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effects [157]. Clinical evaluation of siRNA therapeutics began as early as 2004, but it was mostly
for local administration. Now, the availability of FDA approved siRNA therapeutics bolstered hope
in siRNA therapeutics [14]. Several approaches have been investigated to solve these challenges
that have been thoroughly described in this review. For instance, chemical modification of the
dsRNA has shown in numerous studies to attenuate immune response [158], permit resistance to
endogenous endonucleases and exonucleases [159], improve sequence selectivity to reduce off-target
RNAi activity [160], enhanced cellular permeability [161], and improved antisense strand selectivity by
the RISC complex [162]. Another important factor in enhancing the effectiveness of siRNA therapy is the
sequence selection. The antisense strand in dsRNA is the guide strand for the activation of RISC binding
to the target mRNA. The sequences of the antisense strand is the single most important determinant of
siRNA effectiveness. The sequence selection is not only important on-target potency but also it can
profoundly minimize the off-target RNAi activity [163]. Avoiding the endosomal trap of siRNA and
enhancing its escape for its cytoplasmic activity is a major challenge in RNAi based therapy [164].
Mostly, the siRNA, along with the carriers, enters the cells via endocytosis by interacting with anionic
proteoglycans to form endocytic vesicles. After entry into the cell, the siRNA is entrapped in the
endosomal vesicle, in case, the siRNA delivery system stays trapped in the vesicle, the late endosomal
vesicle becomes acidified by membrane proton pump ATPase. It is relocated to the lysosome, where it
is further acidified, resulting in degradation of the siRNA. Several carriers have been investigated to
enhance the endosomal escape and increased transfection efficiency [45].
Keeping in view the progress made so far in addressing the barriers to siRNA therapy,
numerous ongoing clinical trials in different stages, improved protocols for the systemic administration
of siRNA treatment for targeted therapy, more mature clinical research and development, and the
Good Manufacturing Practices, it is hoped that numerous siRNA based therapies will get approval
from FDA in the years to come. Beyond these novel techniques and modifications in siRNA delivery
systems for enabling the success of siRNA therapeutics, it is much likely that RNAi therapy has several
paths for impactful innovations in challenging diseases over the next decade.
15. Conclusions
Most of the traditional drugs interfere with or modulate the disease-causing proteins. However,
siRNA can silence the expression of the target proteins by interfering with the expression of target
genes. Although it is almost two decades since the discovery of siRNA therapeutics, several challenges
have limited the usefulness of siRNA therapeutics. With a lot of research in addressing those challenges,
and recent emergence of siRNA drugs in the market has garnered a new hope in siRNA therapy.
In this review, we have comprehensively described almost all the challenges pertaining to the success
of siRNA therapy and the innovations and techniques that have been discovered to address those
challenges. Many of the hurdles that were limiting the use of siRNA as an effective tool for the therapy
of intractable disease has been overcome, several clinical trials and great interest by the Pharmaceutical
as well as Biological Companies reveal that we will see some great breakthroughs in the therapy of
cancer and other challenging diseases in the next decade.
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